Shukra Pharmaceuticals Ltd
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing[1]
- Market Cap ₹ 1,821 Cr.
- Current Price ₹ 41.4
- High / Low ₹ 65.3 / 17.1
- Stock P/E 53.6
- Book Value ₹ 2.05
- Dividend Yield 0.02 %
- ROCE 36.9 %
- ROE 28.9 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 20.2 times its book value
- Debtor days have increased from 123 to 148 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|
| 33 | 57 | 75 | |
| 20 | 28 | 28 | |
| Operating Profit | 13 | 29 | 47 |
| OPM % | 39% | 51% | 62% |
| 4 | 5 | 4 | |
| Interest | 1 | 1 | 1 |
| Depreciation | 3 | 3 | 4 |
| Profit before tax | 13 | 29 | 46 |
| Tax % | 28% | 23% | |
| 10 | 22 | 34 | |
| EPS in Rs | 0.22 | 0.50 | 0.76 |
| Dividend Payout % | 0% | 2% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 74% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 130% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 67% |
| 5 Years: | 157% |
| 3 Years: | 139% |
| 1 Year: | 131% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 29% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 44 | 44 |
| Reserves | 19 | 46 |
| 4 | 5 | |
| 20 | 23 | |
| Total Liabilities | 87 | 117 |
| 19 | 22 | |
| CWIP | 2 | 12 |
| Investments | 0 | 0 |
| 65 | 84 | |
| Total Assets | 87 | 117 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| 8 | 4 | |
| -1 | -14 | |
| -5 | 4 | |
| Net Cash Flow | 2 | -6 |
| Free Cash Flow | 5 | -12 |
| CFO/OP | 92% | 19% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Debtor Days | 98 | 148 |
| Inventory Days | 447 | 320 |
| Days Payable | 414 | 232 |
| Cash Conversion Cycle | 131 | 236 |
| Working Capital Days | 403 | 352 |
| ROCE % | 37% |
Insights
In beta| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue share - Commission Income (Other Operating Revenues) % of revenue from operations ・Standalone data |
|
|||||||||
| Revenue share - Sale of Products (Manufacturing) % of revenue from operations ・Standalone data |
||||||||||
| Revenue share - Sale of Services (Jobwork/Contract Manufacturing) % of revenue from operations ・Standalone data |
||||||||||
| Revenue share - Sale of Trading (Traded goods) % of revenue from operations ・Standalone data |
||||||||||
| Permanent employees on rolls count ・Standalone data |
||||||||||
Extracted by Screener AI
Documents
Announcements
-
Reg 30 NSE Listing Done
- Signed term sheet with Borns for 60:40 AI surgical robotics JV in India and APAC.
-
Reg 30 Change Of Name In Object
- Board approved name change to Shukra Medtech and expansion into medical technology, subject to approvals.
-
Reg 30
- Shukra Pharmaceuticals listed on NSE Main Board from 14 August 2026; dual-listed with BSE.
-
Media Release
- Shukra Pharmaceuticals begins NSE trading on 14 August 2026 as SHUKRAPHAR, alongside BSE listing.
- Announcement under Regulation 30 (LODR)-Newspaper Publication
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
SPL is a is WHO-GMP certified integrated manufacturer of formulations like tablet, capsules and small volume parenteral. It has assisted in the development and manufacture
of a variety of drugs and dosage forms and potency variations for many pharmaceutical companies